Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylephrine + Ringer-Acetate is a combination of the vasopressor and decongestant phenylephrine with the balanced electrolyte solution Ringer-Acetate. Phenylephrine is an alpha-1 adrenergic receptor agonist that induces vasoconstriction, raising blood pressure and reducing nasal congestion by narrowing blood vessels[1][3]. It is used intravenously to treat hypotension, especially in surgical or critical care settings. Ringer-Acetate is an isotonic crystalloid solution containing sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride, and sodium acetate in water; it serves as a plasma volume expander to replace fluids and electrolytes lost due to illness or injury[5]. The combination may be used in intensive care for hemodynamic support where both fluid resuscitation and vasopressor therapy are required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylephrine + Ringer-Acetate.